Related Experiment Video
Updated: Aug 6, 2025

Comparative Lesions Analysis Through a Targeted Sequencing Approach
Published on: November 5, 2019
Whole-exome sequencing of secondary tumors arising from nevus sebaceous revealed additional genomic alterations
Yoon-Seob Kim1, Gyeong Sin Park2, Yeun-Jun Chung3,4
1Department of Dermatology, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Abstract:
Nevus sebaceous (NS) is a congenital hamartoma associated with an increased risk of secondary neoplasms in approximately 10%-20% of patients. However, additional genomic alterations underlying tumorigenesis in NS lesions have not been clarified. We performed whole-exome sequencing of archived tumor tissues (n = 8; six basal cell carcinomas and two trichoepitheliomas) and matched germline tissues (n = 7) with from seven patients with secondary tumors arising from NS. We also analyzed NS lesions without secondary tumors (n = 8). Somatic mutations and copy number alterations (CNAs) were analyzed. We identified a median of 129 somatic mutations (corresponding to 2.6/Mb in target regions, range 26-336) for eight tumors, while a median of 118 somatic mutations (2.3/Mb, range 1-196) for eight NS lesions. Known RAS hotspot mutations were found in seven of the eight tumors (six for HRAS p.G13R and one for HRAS p.Q61R) and in six of the eight NS lesions (four for HRAS p.G13R, one for KRAS p.G12C, and one KRAS p.G12D). Except RAS mutations, several putative driver mutations were detected in tumors: TP53 p.F134L/p.R213*, MYCN p.P59L, OR2Z1 p.P167S, PTPN14 p.Q768*, and SMO p.W535L. As for CNAs, two tumors harbored copy-loss in regions encompassing PTCH1 gene. However, eight NS lesions did not harbor both putative driver mutations and CNAs. In conclusion, our study revealed that secondary tumors arising from NS harbor known RAS hotspot mutations and additional genomic alterations, including putative driver mutations and PTCH1 copy-loss. These results could help to define the high-risk group for tumor development in patients with NS and provide evidence for prophylactic resection.
Insights
Secondary tumors in nevus sebaceous (NS) harbor RAS mutations and additional genomic alterations. Understanding these genetic changes can help identify high-risk patients for proactive treatment.
Area of Science:
- Oncology
- Genetics
- Dermatology
Background:
- Nevus sebaceous (NS) is a congenital hamartoma with a 10-20% risk of secondary tumors.
- The specific genomic alterations driving tumorigenesis in NS remain largely unclear.
Purpose of the Study:
- To investigate the genomic landscape of secondary tumors arising from NS.
- To identify genetic alterations that differentiate malignant transformation in NS lesions.
Main Methods:
- Whole-exome sequencing was performed on tumor and matched germline tissues from patients with secondary tumors originating from NS.
- Analysis included somatic mutations and copy number alterations (CNAs) in both tumor tissues and NS lesions without secondary tumors.
Main Results:
- Secondary tumors frequently harbored RAS hotspot mutations (HRAS, KRAS).
- Additional putative driver mutations (TP53, MYCN, OR2Z1, PTPN14, SMO) and PTCH1 copy-loss were identified in tumors.
- NS lesions without secondary tumors showed fewer mutations and lacked these specific driver alterations.
Conclusions:
- Secondary tumors in NS are characterized by RAS mutations and distinct genomic alterations, including PTCH1 copy-loss.
- These findings aid in defining high-risk NS patients and support considering prophylactic resection.
More Related Videos
Related Concept Videos
Cancers Originate from Somatic Mutations in a Single Cell
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
The Ras Gene
Ras is a...
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Abnormal Proliferation

